With the theme of “Only the innovators can make steady progress”, the press conference of the 2021 Chinese Biopharma Companies Innovation TOP 100 Series Lists was held online on September 16, 2022. Genor Biopharma remained included in the Chinese Antibody Drug Companies Innovation TOP 30.
Last year, with the unremitting pursuit of core technology innovation capability, as well as the active expansion in early R&D and commercial manufacturing, Genor Biopharma deeply impressed MENET and experts from the Expert Committee of Chinese Biopharma Companies Innovation TOP 100, and made the first Chinese Biopharma Companies Innovation TOP 100 Series Lists – “Chinese Antibody Drug Companies Innovation TOP 30".
In the past year, Genor Biopharma successfully established a research and development platform for the early discovery of global FIC/BIC potential, differential bi-specific/multi-specific antibodies in immune-oncology; achieved rapid advancement far beyond the industry overall in a number of key clinical trials; and obtained approval for Jiayujian® (GB242, infliximab) which is used for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's Disease and fistulising Crohn’s Disease.
